primatron, page-5

Do not under estimate the significance of these results. From a scientific perspective they are significant.
The Biomira election is neither here nor there sometimes companies in their position choose to go in a different direction purely because their base focus changes.
I no longer hold shares in this company. I sold out with a significant loss some months back. I do however wish the company well for the future solely on the basis ovarian cancer is a horrific disease with an extremely poor prognosis unless there is early detection.
The reality is, if this company had a good management team in place with a sound corporate history and market credibility then the company's shareprice would be well advanced on today's close.
Based purely on the technology it could be a real winner. Whether the management in place can turn this company around and generate shareholder returns in it's current form remains debatable.